Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06287073
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-02-23
Brief Title:
JARDIANCE Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease CKD
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE Empagliflozin 10 mg in Korean Patients With Chronic Kidney Disease CKD
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to monitor the safety profile of JARDIANCE in Korean patient with chronic kidney disease CKD in routine clinical practice
The secondary objective is to monitor the efficacy of JARDIANCE by evaluating changes in urine albumin-creatinine ratio UACR after 12 andor 24 weeks of treatment
The secondary objective is to monitor the efficacy of JARDIANCE by evaluating changes in urine albumin-creatinine ratio UACR after 12 andor 24 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUPAS107293 | REGISTRY | EU PAS Register | None |